INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
86.07
+1.97 (+2.34%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close84.10
Open84.08
Bid83.43 x 800
Ask87.01 x 900
Day's Range84.50 - 86.11
52 Week Range57.00 - 89.30
Volume655,765
Avg. Volume1,184,035
Market Cap18.511B
Beta (3Y Monthly)0.91
PE Ratio (TTM)60.57
EPS (TTM)1.42
Earnings DateOct 28, 2019 - Nov 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est91.67
Trade prices are not sourced from all markets
  • Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer
    Zacks

    Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer

    Celgene's (CELG) oncology portfolio gets a boost with the FDA approval of Inrebic for rare bone marrow cancer.

  • 3 Charts That Suggest Now Is the Time to Buy Into Biotech
    Investopedia

    3 Charts That Suggest Now Is the Time to Buy Into Biotech

    Most of the financial markets have trended lower in recent weeks, but biotech seems to have countered the trend.

  • Does Incyte (NASDAQ:INCY) Have A Healthy Balance Sheet?
    Simply Wall St.

    Does Incyte (NASDAQ:INCY) Have A Healthy Balance Sheet?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • GlobeNewswire

    BriaCell Appoints Richard J. Berman to Board of Directors

    BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.

  • Top Biotech Stocks for February 2019
    Investopedia

    Top Biotech Stocks for February 2019

    Biotech a thrilling industry for investors, and one with tremendous opportunity for gains, as shown in early 2019, but it is notably risky for investors, too.

  • Thomson Reuters StreetEvents

    Edited Transcript of INCY earnings conference call or presentation 30-Jul-19 12:00pm GMT

    Q2 2019 Incyte Corp Earnings Call

  • Incyte Corp (INCY) Q2 2019 Earnings Call Transcript
    Motley Fool

    Incyte Corp (INCY) Q2 2019 Earnings Call Transcript

    INCY earnings call for the period ending July 30, 2019.

  • The No. 1 Biotech Is Flirting With A Buy Point After Its Beat-And-Raise
    Investor's Business Daily

    The No. 1 Biotech Is Flirting With A Buy Point After Its Beat-And-Raise

    Incyte stock approached a buy point Tuesday after the top-rated biotech company crushed second-quarter sales and earnings estimates and raised its 2019 outlook for cancer treatment Jakafi.

  • Here's What You'll Want to Know About Incyte's Impressive Q2 Results
    Motley Fool

    Here's What You'll Want to Know About Incyte's Impressive Q2 Results

    The biotech beat Wall Street revenue and earnings estimates in Q2. And it could have more good news on the way.

  • Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y
    Zacks

    Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y

    Incyte (INCY) reports better-than-expected results for the second quarter of 2019, owing to strong Jakafi sales.

  • Incyte (INCY) Q2 Earnings and Revenues Beat Estimates
    Zacks

    Incyte (INCY) Q2 Earnings and Revenues Beat Estimates

    Incyte (INCY) delivered earnings and revenue surprises of 53.06% and 5.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

    WILMINGTON, Del.-- -- Total product and royalty revenues of $510 million and Jakafi ® revenues of $410 million for the quarter ended June 30, 2019; raising the bottom end of full year 2019 Jakafi revenue guidance to a new range of $1.61-1.65 billion Accomplished multiple key development goals for H1 2019, including FDA approval of Jakafi for steroid-refractory acute graft-versus-host disease and the ...

  • Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
    Zacks

    Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

    Investors will focus on top- and bottom-line numbers along with other pipeline updates, when Zoetis reports Q2 results.

  • 4 Biotech Stocks Sliding Lower
    InvestorPlace

    4 Biotech Stocks Sliding Lower

    U.S. equities slipped lower on Thursday as investors continued to digest a heavy flow of earnings reports. There have been some disappointment as well surrounding a lack of specifics from European Central Bank President Mario Draghi, who has been jawboning fresh stimulus but hasn't yet actually taken action.Some weakness in key industrial and technology stocks has weighed on sentiment. Now, biotech stocks are coming under pressure as well. The Nasdaq Biotechnology ETF (NASDAQ:IBB) is falling away from its 200-day moving average, falling down what looks like the right shoulder of a head-and-shoulders reversal pattern going back to 2017. * 7 Oversold Stocks To Buy Right Now Here are four biotech stocks helping lead the decline:InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech Stocks: Vertex Pharmaceuticals (VRTX)Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) stock, which focuses on cystic fibrosis treatments, are falling away from their 50-day and 200-day moving averages to return to the April-June trading range. This marks the latest test of uptrend channel support going back to late 2017. Coverage of this biotech stock was recently resumed at Citigroup, which assigned a buy rating and a $205 price target.The company will next report results on July 31 after the close. Analysts are looking for earnings of $1.08 per share on revenues of $886.3 million. When the company last reported on April 30, earnings of $1.14 beat estimates by 13 cents per share on a 34.3% rise in revenues. Regeneron Pharmaceuticals (REGN)Shares of Regeneron Pharmaceuticals (NASDAQ:REGN), maker of treatments including EYLEA for wet age-related macular degeneration, have fallen back below their 50-day moving average and look set for a test of vital support near its early 2018 lows around $290. This marks the bottom of a trading range going all the way back to 2014, so a breakdown would open the door to a major reversal of the gains posted between 2010 and 2015 that resulted in a 23x rally. * 7 Stocks to Sell This Summer Earnings Season The company will next report results on Aug. 6 before the bell. Analysts are looking for earnings of $5.44 per share on revenues of $1.8 billion. When the company last reported on May 7, earnings of $4.45 missed estimates by $1.07 per share on a 13.3% rise in revenues. Alexion Pharmaceuticals (ALXN)Shares of Alexion Pharmaceuticals (NASDAQ:ALXN), which makes various medications including a treatment for genetic blood disorders, are falling away from their 200-day moving average to threaten a decline below its late May low near $115. This marks nearly a 20% decline from its April high.The company reported better-than-expected results on Wednesday, with earnings of $2.64 per share beating estimates by 30 cents. Forward guidance was raised as well. Yet it appears the whisper number was higher, as investors sold on the report. The company will next report results on Oct. 23 before the market. Incyte (INCY)Shares of Incyte (NASDAQ:INCY) stock, which is a maker of various cancer treatments among other drugs, is falling away from double-top resistance near the $90-a-share threshold and is once again threatening a decline below its 200-day moving average. Shares enjoyed a lift last month on the premium purchase of Array BioPharma (NASDAQ:ARRY), maker of treatment for certain BRAF-mutant cancers, by Pfizer (NYSE:PFE). * 10 Stocks to Buy From This Superstar Fund The company will next report results on July 30 before the bell. Analysts are looking for earnings of 49 cents per share on revenues of $496.6 million. When the company last reported on April 30, earnings of 62 cents per share beat estimates by 21 cents on a 30.2% rise in revenues.As of this writing, William Roth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Oversold Stocks To Buy Right Now * 7 Stocks to Buy Upgraded by Wall Street * 7 Marijuana Stocks With Critical Levels to Watch The post 4 Biotech Stocks Sliding Lower appeared first on InvestorPlace.

  • Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings?
    Zacks

    Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings?

    Investors are expected to focus on the HIV franchise's performance and other pipeline updates, when Gilead (GILD) reports second-quarter 2019 results.

  • Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings?
    Zacks

    Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings?

    Investors will primarily focus on Jakafi sales and pipeline updates, when Incyte (INCY) reports second-quarter 2019 results.

  • 5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2
    Zacks

    5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2

    We take a look at the overall drug/biotech sector's performance and five stocks that are poised to beat on earnings in the second quarter of 2019.

  • Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks

    Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    BriaCell Announces $350,000 Equity Investment by Board of Directors

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it intends to complete a non-brokered private placement of up to 5,000,000 common shares of the Company at a price of C$0.07 per common share for gross proceeds of up to approximately C$350,000 (the “Offering”).

  • Business Wire

    Incyte to Report Second Quarter Financial Results

    Incyte Corporation announced today that it has scheduled its second quarter 2019 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 30, 2019.

  • Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA
    Zacks

    Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA

    FDA accepts Merck's (MRK) sBLAs for a six-week dosing schedule of Keytruda for melanoma and multiple other indications

  • GuruFocus.com

    5 Immunotherapy Stocks to Keep a Close Eye On

    Immunotherapy is changing the face of cancer treatment as we know it, creating compelling investment opportunities

  • Markit

    See what the IHS Markit Score report has to say about Incyte Corp.

    Incyte Corp NASDAQ/NGS:INCYView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for INCY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $4.30 billion over the last one-month into ETFs that hold INCY are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.